These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 23429980)

  • 1. Escitalopram tolerability as mono- versus augmentative therapy in patients with affective disorders: a naturalistic study.
    Dell'osso B; Arici C; Dobrea C; Camuri G; Benatti B; Altamura AC
    Neuropsychiatr Dis Treat; 2013; 9():205-9. PubMed ID: 23429980
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Antipsychotics in bipolar disorders].
    Vacheron-Trystram MN; Braitman A; Cheref S; Auffray L
    Encephale; 2004; 30(5):417-24. PubMed ID: 15627046
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Duloxetine in affective disorders: a naturalistic study on psychiatric and medical comorbidity, use in association and tolerability across different age groups.
    Dell'osso B; Camuri G; Dobrea C; Buoli M; Serati M; Altamura AC
    Clin Pract Epidemiol Ment Health; 2012; 8():120-5. PubMed ID: 23166563
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Double-blind comparison of escitalopram and duloxetine in the acute treatment of major depressive disorder.
    Khan A; Bose A; Alexopoulos GS; Gommoll C; Li D; Gandhi C
    Clin Drug Investig; 2007; 27(7):481-92. PubMed ID: 17563128
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Paroxetine : a review of its pharmacology and therapeutic potential in the management of panic disorder.
    Foster RH; Goa KL
    CNS Drugs; 1997 Aug; 8(2):163-88. PubMed ID: 23338224
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Escitalopram therapy for major depression and anxiety disorders.
    Baldwin DS; Reines EH; Guiton C; Weiller E
    Ann Pharmacother; 2007 Oct; 41(10):1583-92. PubMed ID: 17848424
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tolerability and use in co-administration of pregabalin in affective patients: a 6-month prospective naturalistic study.
    Dobrea C; Buoli M; Arici C; Camuri G; Dell'Osso B; Altamura AC
    Expert Opin Drug Saf; 2012 Nov; 11(6):893-9. PubMed ID: 22946673
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Safety and efficacy of oral escitalopram as continuation treatment of intravenous citalopram, in patients with major depressive disorder--the navigade switch study].
    Schmitt L; Arbus C; Tonnoir B
    Encephale; 2006; 32(2 Pt 1):270-7. PubMed ID: 16910629
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of escitalopram and citalopram in outpatients with severe major depressive disorder: a prospective, naturalistic, 8-week study.
    Lançon C; Sapin C; Note I; Farisse J
    Int J Psychiatry Clin Pract; 2006; 10(2):131-7. PubMed ID: 24940963
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and tolerability of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, prospective, randomized, double-blind, active-controlled study in adult outpatients.
    Yevtushenko VY; Belous AI; Yevtushenko YG; Gusinin SE; Buzik OJ; Agibalova TV
    Clin Ther; 2007 Nov; 29(11):2319-32. PubMed ID: 18158074
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early non-response in patients with severe depression: escitalopram up-titration versus switch to duloxetine.
    Bose A; Tsai J; Li D
    Clin Drug Investig; 2012 Jun; 32(6):373-85. PubMed ID: 22559255
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of lithium in children and adolescents with conduct disorder: a retrospective naturalistic study.
    Masi G; Milone A; Manfredi A; Pari C; Paziente A; Millepiedi S
    CNS Drugs; 2009; 23(1):59-69. PubMed ID: 19062775
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Escitalopram: a pharmacoeconomic review of its use in depression.
    Croom KF; Plosker GL
    Pharmacoeconomics; 2003; 21(16):1185-209. PubMed ID: 14594439
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Duloxetine versus escitalopram and placebo: an 8-month, double-blind trial in patients with major depressive disorder.
    Pigott TA; Prakash A; Arnold LM; Aaronson ST; Mallinckrodt CH; Wohlreich MM
    Curr Med Res Opin; 2007 Jun; 23(6):1303-18. PubMed ID: 17559729
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved insomnia symptoms and sleep-related next-day functioning in patients with comorbid major depressive disorder and insomnia following concomitant zolpidem extended-release 12.5 mg and escitalopram treatment: a randomized controlled trial.
    Fava M; Asnis GM; Shrivastava RK; Lydiard B; Bastani B; Sheehan DV; Roth T
    J Clin Psychiatry; 2011 Jul; 72(7):914-28. PubMed ID: 21208597
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety of 80 antidepressants, antipsychotics, anti-attention-deficit/hyperactivity medications and mood stabilizers in children and adolescents with psychiatric disorders: a large scale systematic meta-review of 78 adverse effects.
    Solmi M; Fornaro M; Ostinelli EG; Zangani C; Croatto G; Monaco F; Krinitski D; Fusar-Poli P; Correll CU
    World Psychiatry; 2020 Jun; 19(2):214-232. PubMed ID: 32394557
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy, Safety and Tolerability of Augmentative rTMS in Treatment of Major Depressive Disorder (MDD): A Prospective Cohort Study in Croatia.
    Filipcic I; Milovac Z; Sucic S; Gajsak T; Filipcic IS; Ivezic E; Aljinovic V; Orgulan I; Penic SZ; Bajic Z
    Psychiatr Danub; 2017 Mar; 29(1):31-38. PubMed ID: 28291972
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An open-label, rater-blinded, flexible-dose, 8-week trial of escitalopram in patients with major depressive disorder with atypical features.
    Pae CU; Masand PS; Peindl K; Mannelli P; Han C; Marks DM; Patkar AA
    Prim Care Companion J Clin Psychiatry; 2008; 10(3):205-10. PubMed ID: 18615172
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Escitalopram and duloxetine in major depressive disorder: a pharmacoeconomic comparison using UK cost data.
    Wade AG; Fernández JL; François C; Hansen K; Danchenko N; Despiegel N
    Pharmacoeconomics; 2008; 26(11):969-81. PubMed ID: 18850765
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Escitalopram: in the treatment of major depressive disorder in adolescent patients.
    Yang LP; Scott LJ
    Paediatr Drugs; 2010 Jun; 12(3):155-63. PubMed ID: 20481645
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.